Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-228 and TAK-117 with Paclitaxel in Advanced Solid Tumors
NCT03154294Phase 1Completed
- Sponsor
- Avera McKennan Hospital & University Health Center
- Start
- Jul 2017
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sapanisertib and serabelisib in solid tumor (advanced stage) (5 cohorts), sponsored by Avera McKennan Hospital & University Health Center. Primary endpoint: Dose-limiting Toxicity at 30 days. Started Jul 2017; status: completed.
02
Drugs
sapanisertibserabelisib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03154294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03154294.